A Multicenter Study of the Efficacy of Cerezyme in Testing Skeletal Disease in Patients With Type I Gaucher Disease.

Condition(s) targeted: Gaucher Disease Type I; Cerebroside Lipidosis Syndrome; Clucocerebrosidase Deficiency Disease; Glucosylceramide Beta-Glucosidase Deficiency Disease; Gaucher Disease, Non-Neuronopathic Form

Intervention: Cerezyme (imiglucerase for injection) (Drug)

Phase: Phase 4

Status: Completed

Sponsored by: Genzyme

Official(s) and/or principal investigator(s):
Edward M. Kaye, M.D., Study Director, Affiliation: Genzyme

This is a multicenter, open-label, prospective study of the efficacy of Cerezyme in treating patients with skeletal manifestations secondary to Type I Gaucher disease.

The study objective is to evaluate and quantify skeletal responses as compared to baseline in Type I gaucher disease patients receiving Cerezyme therapy for 48 months. Additional objectives were to assess the usefulness of various skeletal parameters, such as bone pain, bone crises, bone mineral density, and serum and urine bone markers, as indicative of treatment response and may be useful in dose management.

Study design: Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Efficacy Study

Primary outcome:

Skeletal response over 4 years of Cerezyme therapy

Assess use of skeletal parameter as indicative of treatment response and use in dose management

Minimum age: 10 Years. Maximum age: 65 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Signed informed consent.

- Confirmed diagnosis of Type I Gaucher disease, with no prior enzyme replacement

therapy, gene therapy or bone marrow transplantation, and who are ambulatory.

- Age 10-65 (patients 66-70 years of age are considered on a case-by-case basis

following careful medical review).

- Dual energy X-ray absorptiometry (DEXA) of the femoral nech with a T-score ≤ -1. 0.

- One of more of the following signs as documented by X-ray, computed tomography (CT),

or magnetic resonance imaging (MRI), or symptoms of bone disease as documented in the patient’s medical history or baseline examinations: a). history of at least one bone crises; b). Erlenmeyer flask deformity of the femora in children (10-17 years old); c). osteoarticular necrosis; d). medullary infarctions; e). lytic lesions; f). pathological fractures or fractures related to Gaucher disease; g). marrow infiltration to a degree such that Rosenthal’s Magnetic Resonance Score was ≥ 3; h). bone density by quantitative computed tomography (QCT) or DEXA ≥ 1. 5 standard deviation (SD) below age-adjusted normal value; and i). fat fraction ≤ 17%.

Exclusion Criteria:

- More than 1 joint replacement (revision surgery such as repair or replacement of a

previously replaced joint is allowed).

- Pregnant, lactating or per-menopausal women.

- Active, uncontrolled infection, such as hepatitis B, hepatitis C or human

immunodeficiency virus (HIV).

- Major concurrent disorders (i. e. cancer, renal disease) or disorders known to affect

bone (e. g. uncontrolled thyroid disease, hyperparathyroidism, hypoparathyroidism, gastrectomy, malabsorption, inflammatory bowel disease, rheumatoid arthritis, ankylosing spondylitis).

- Medications known to affect bone homeostasis (e. g. chronic oral corticosteroids,

anticonvulsants, phenytoin and phenobarbital, hyper-physiological doses of estrogen, defined as > 0. 625mg, or androgens, bisphosphates, calcitonin) within the first 2 months of the first Cerezyme infusion.

- Emotional, behavioral or psychological problems, which in the judgment of the

principal investigator, would interfere with the patient adequately complying with the requirement of the study.

Coral Springs, Florida 33065, United States

Results synopsis for RC96-1101

US FDA Approved Full Prescribing Information for Cerezyme®

Starting date: December 1997
Last updated: July 16, 2007